Sotorasib Tablets Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Sotorasib Tablets Market Forecast: What Market Value Is Expected By 2030?
The market for sotorasib tablets has experienced rapid expansion in recent years. Projected to increase from $1.92 billion in 2025 to $2.16 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 12.3%. Several factors have driven this historic period’s progress, including a rising number of non-small cell lung cancer diagnoses, breakthroughs in KRAS mutation research, regulatory clearances for targeted cancer therapies, broader availability of molecular diagnostic tools, and an uptick in oncology clinical trials.
The projected value of the sotorasib tablet market is anticipated to expand rapidly in the coming years. By 2030, it is forecast to reach $3.4 billion, reflecting a compound annual growth rate (CAGR) of 12.0%. This growth during the forecast period can be explained by the rising development of next-generation KRAS inhibitors, the growing adoption of combination therapeutic approaches, the expansion of targeted treatments into additional cancer indications, the increased use of real-world evidence studies, and the broader implementation of precision medicine in oncology. Key developments expected during this period include a greater uptake of KRAS G12C inhibitor therapies, an intensified focus on targeted treatments for lung cancer, a rise in the use of oral oncology medications, an expansion of companion diagnostic testing, and improved surveillance of resistance mechanisms.
Download A Free Sample Report For Comprehensive Market Insights:
#Sotorasib Tablets Market Growth Factors: Which Forces Are Supporting Market Expansion?
The anticipated growth of the sotorasib tablets market is being driven by the increasing incidence of cancer. Cancer encompasses a range of diseases characterized by the uncontrolled proliferation of abnormal cells, which invade surrounding tissues and may metastasize to other areas of the body. This rise in cancer cases is largely attributed to an aging population, as advanced age stands as the primary risk factor for most cancer types, with the majority of diagnoses occurring in individuals over 65. Sotorasib tablets function by selectively and irreversibly binding to the KRAS G12C mutation, effectively locking the mutated protein in an inactive state to halt uncontrolled cell division in patients with advanced solid tumors, particularly non-small cell lung cancer. For example, in February 2024, the World Health Organization, a Switzerland-based international body focused on global health policy and public health initiatives, projected over 35 million new cancer cases by 2050, marking a 77% rise from the estimated 20 million cases in 2022. Consequently, the growing prevalence of cancer is fueling expansion in the sotorasib tablets market.
The sotorasib tablets market is expected to be propelled forward by the expanding geriatric population. This demographic, consisting of older adults typically aged 65 and above, often faces age-related physiological, psychological, and social changes. The growth in this population segment is largely driven by increased life expectancy, resulting from improvements in healthcare, nutrition, and living conditions that enable more individuals to live longer, thereby raising the proportion of older adults. Sotorasib tablets benefit the geriatric population by specifically targeting KRAS G12C-mutated cancers, delivering a precision therapy that mitigates age-related vulnerabilities and enhances treatment outcomes for older patients. As an illustration, in July 2024, the UK Parliament’s House of Commons Library, a UK-based government administration, reported that in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This figure is projected to increase to 22.1 million by 2072, accounting for 27% of the population. Thus, the rising geriatric population is driving growth in the sotorasib tablets market.
Sotorasib Tablets Market Segment Breakdown: Which Categories Generate The Most Revenue?
The sotorasib tablets market covered in this report is segmented –
1) By Dosage Form: 40 Milligrams (Mg) Tablets, 120 Milligrams (Mg) Tablets, 240 Milligrams (Mg) Tablets, Other Dosage Forms
2) By Patient Demographics: Adolescents, Adult, Senior Adults
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By Application: Non-Small Cell Lung Cancer, Colorectal Cancer, Other Applications
5) By End-User: Hospitals, Oncology Centers, Clinics, Other End-Users
Sotorasib Tablets Market Industry Trends: What Changes Are Reshaping Demand?
Major players in the sotorasib tablet market are prioritizing the development of cutting-edge therapies, including combination regimens, aimed at enhancing treatment effectiveness and addressing resistance issues. A combination treatment involves the simultaneous use of two or more drugs to attack cancer via diverse mechanisms, thereby boosting therapeutic success, delaying or preventing drug resistance, lowering the chances of cancer returning, and enhancing overall patient well-being and life quality. As an example, in January 2025, Amgen Inc., a biotechnology firm based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for sotorasib combined with panitumumab to treat adult patients suffering from KRAS G12C–mutated metastatic colorectal cancer (mCRC) who had already undergone standard chemotherapy. This authorization was grounded in findings from the Phase 3 CodeBreaK 300 trial, which revealed that the duo more than doubled progression-free survival relative to the investigator’s selected standard-of-care therapy, thus providing a notable fresh option for individuals facing this challenging cancer type. Sotorasib stands as a groundbreaking oral KRAS G12C inhibitor that functions by precisely targeting and securing the mutant KRAS protein in its dormant form, thus hindering cancer cell proliferation and the signaling pathways propelled by this mutation.
Sotorasib Tablets Market Key Players And Strategic Industry Positioning
Major companies operating in the sotorasib tablets market are Amgen Inc.
Access The Complete Sotorasib Tablets Market Report:
Sotorasib Tablets Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the sotorasib tablets market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotorasib tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
